How Much Can Cancer Treatment in China Cost?
Cancer treatment cost in China depends on the cancer, stage, treatment, hospital and whether the patient pays as an international self-pay case. There is no universal price, because hospitals do not share one tariff. A published or example figure is not a case-specific estimate, and an estimate is not the final bill. Medical records are how a review can define the treatment scope. Sending them does not guarantee treatment, eligibility, acceptance, a price or a response time.
Medical records → case review → treatment scope → cost estimate / next step
✓ Independent studies separated from provider claims
✓ Product price separated from full episode cost
✓ Historical fees labelled historical
✓ Published figures are not a case-specific estimate
Which Cost Figures Are Reliable — and Which Are Not
Published ranges for surgery, chemotherapy, immunotherapy, proton therapy and CAR-T often disagree. A generic web range is not a national tariff.
Independent patient-cost studies
Useful for understanding real financial burden and cost drivers in China. Not equivalent to an international self-pay quote.
Peer-reviewed CAR-T list prices
Useful as product-price snapshots. They do not include every hospital, procedure, monitoring or complication cost.
2026 satri-cel price
A current Shanghai government information source reports RMB 990,000 for a course. The approved indication is narrow and eligibility matters.
SPHIC and FUDA examples
Useful only when clearly labelled by date and source. They are not universal China-wide 2026 prices.
Not used as national prices: generic web tables such as “surgery USD 3,000–25,000,” “chemotherapy USD 1,000–3,000 per cycle,” or one universal “full-course” China price. Those ranges conflict with each other, so they are not listed as national prices.
Provider Cost & Access Snapshot (Not a Ranking)
These three Guangzhou centres appear often in international patient research. This table is a non-ranked access and cost-status snapshot — not a “best hospital” list. Fit depends on disease, stage, prior treatment and what each centre can actually open for a foreign case.
| Provider | Location | Relevant capability (cautious) | International access status | Known cost info | Next step |
|---|---|---|---|---|---|
| Fuda Cancer Hospital | Guangzhou | Interventional and minimally invasive oncology. This is not a claim that the hospital is the best choice for every cancer. | Pre-arrival case submission available (coordination path). Written estimate after case review where applicable. | Case-dependent — no fixed public package price. | Fuda Cost guide |
| Modern Cancer Hospital Guangzhou (St. Stamford) | Guangzhou | Licensed medical facility. Lists of methods in its marketing are not independent proof of results. | Ask the hospital. Its marketing claims about international access are not confirmed here. | Quotation required after case review. Marketing fee claims are not published here as official prices. | Modern Cost guide (screening / quote path) |
| Sun Yat-sen University Cancer Center (SYSUCC) | Guangzhou | Oncology centre with a documented pre-arrival file review and appointment path. Remote treatment-plan issuance before arrival is not confirmed. | Pre-arrival file review available. Remote treatment plan not confirmed. | Prices not publicly fixed — quotation after file review / appointment path. | SYSUCC guide · SYSUCC Cost guide |
Pricing reality check: final treatment pricing comes from the hospital/provider after case review where applicable.
Published studies, historical procedure fees and product list prices on this page are evidence categories — not a substitute for a case-specific hospital quote.
Published Cost Data: Source, Population and Limits
A number is useful only when the population, year and cost category are clear.
| Published data point | Source / date | What it measures | What it does NOT mean |
|---|---|---|---|
| Initial treatment: USD 6,359–13,704 median total cost | 2024 cost-of-illness study; 13,745 patients; 84 hospitals; 17 provinces; 2021–2022 data | Patient-borne total cost ranges across six leading cancers during initial treatment | Not a 2026 international-patient package and not one cancer-specific quote |
| Relapse/metastasis: USD 8,890–14,572 Follow-up: USD 1,840–4,431 | Same 2024 multicentre study | Median per-case total costs by treatment phase | Not a hospital tariff; insurance and domestic patient context matter |
| Annual mean medical costs: USD 7,421–10,297 | 2023 systematic review of 38 quantitative studies | Studies including inpatient, outpatient and self-purchased medicines | Not a current foreign-patient quote; underlying studies span earlier years |
| CAR-T product list prices: RMB 999,000–1.29 million / infusion | 2024 peer-reviewed pricing paper covering five China-approved CAR-T products at that time | Drug / cell-product list price | Not the full episode: conditioning, procedures, facility, monitoring and toxicity care can add cost |
| Satri-cel: RMB 990,000 / course | Shanghai official information platform, 20 Aug 2026 | Current reported course price for the newly commercialised solid-tumour CAR-T product | Not a universal CAR-T price and not automatically the complete hospital episode |
| SPHIC particle course: nearly RMB 278,000 | China National Health Commission / China Daily report, 2016 | Historical official price for a typical radiation course around the centre’s opening period | Not the current 2026 SPHIC tariff; request a fresh written quote |
| FUDA examples: tens of thousands to > RMB 1 million depending on case | FUDA official article, 20 Sep 2025 | Provider-published domestic examples by cancer type and treatment | Not independent evidence and not a guaranteed foreign-patient price |
Independent China Cost Data: The Best Starting Point
The study covered lung, breast, colorectal, esophageal, liver and gastric cancers across 84 hospitals in 17 provinces. Relapse/metastasis was the most expensive treatment phase and advanced stage increased cost.
In adjusted analyses, specialised hospitals were associated with about 30% higher direct medical costs than general hospitals. Eastern and southern regions were also higher than northern regions, while western regions were lower. These are population-level associations, not a rule for a specific hospital.
Important for international patients: independent studies measure the economic burden borne by patients
in China’s domestic health system. They are stronger evidence than travel-marketplace lists, but they still do not answer
“What will this hospital charge me as a foreign self-pay patient?” That requires a case-specific international estimate.
CAR-T Cost in China: Product Price Is Not the Full Bill
CAR-T is one area where published product prices are easier to verify than generic “cancer package” prices.
| Product snapshot | Published list price in the 2024 peer-reviewed paper | Target / indication category at the time |
|---|---|---|
| Axicabtagene ciloleucel (Yikaida) | RMB 1.20 million | CD19 / selected relapsed-refractory LBCL |
| Relmacabtagene autoleucel (Carteyva) | RMB 1.29 million | CD19 / selected relapsed-refractory LBCL |
| Equecabtagene autoleucel (FUCASO) | RMB 1.166 million | BCMA / selected relapsed-refractory multiple myeloma |
| Inaticabtagene autoleucel (Yuanruida) | RMB 999,000 | CD19 / selected relapsed-refractory B-ALL |
| Zevorcabtagene autoleucel | RMB 1.15 million | BCMA / selected relapsed-refractory multiple myeloma |
2024 snapshot: this documents published list prices at that time. China’s commercial CAR-T catalogue has
continued to change. Confirm the current product, indication, availability and price with the treating centre.
See the dedicated CAR-T Therapy in China guide.
Satri-cel in 2026: A Current Price With a Very Specific Indication
Chinese government reporting says satricabtagene autoleucel was approved for CLDN18.2-positive, HER2-negative unresectable advanced gastric or gastroesophageal-junction adenocarcinoma after progression following at least two prior lines of treatment.
Shanghai’s official information platform reported this price on 20 August 2026 during commercial rollout. It is a product/course price reference, not automatically the complete hospital invoice.
Evidence context: in the randomised phase 2 CT041-ST-01 trial, median progression-free survival was
3.25 months with satri-cel versus 1.77 months with physician’s-choice treatment. Grade 3 or higher treatment-emergent
adverse events occurred in 99% versus 63%; cytokine release syndrome occurred in 95% of satri-cel recipients.
Proton and Heavy-Ion Therapy: Keep the RMB 278,000 Figure in Its Historical Context
China’s National Health Commission reported in 2016 that a typical radiation course at the newly opened Shanghai Proton
and Heavy Ion Center cost nearly RMB 278,000. That is a strong primary-source historical reference.
It is not sufficient evidence that every SPHIC course still costs RMB 278,000 in 2026.
First confirm that particle therapy is clinically appropriate, then request the current treatment plan, modality, fraction schedule, planning imaging, expected visits and written 2026 estimate. See Proton Therapy in China.
FUDA’s Published Price Examples: Useful Provider Data, Not a National Benchmark
FUDA published a cost explainer on 20 September 2025. It is useful provider data, not an independent national price benchmark.
| FUDA-published example | Published amount | What the figure is |
|---|---|---|
| Early-stage lung cancer surgery, smooth recovery | RMB 50,000–100,000 | Provider example only |
| Early-stage laparoscopic surgery | RMB 50,000–80,000 | Provider example only |
| Open chest / abdominal advanced surgery | RMB 150,000+ | Provider example only |
| Robotic-assisted surgery | RMB 80,000–120,000 | Provider example only |
| PET-CT | RMB 7,000–10,000 | Provider example only |
| Chemotherapy | Several thousand to > RMB 10,000 per cycle; total may reach tens of thousands to > RMB 100,000 | Highly regimen-dependent provider range |
Do not read these as package prices for every patient. International-patient billing can differ from these domestic examples. They are not a case-specific estimate or a final bill.
For FUDA-specific billing, use the FUDA Cost guide.
Eight Things a Real Cancer-Treatment Quote Must Separate
Cancer, stage and line
“Cancer” is not a billable protocol. Stage, pathology and treatment line determine the basket.
Surgery, drugs, radiation or cells
Different treatment classes have fundamentally different cost structures.
Exact drug or cell product
For CAR-T and targeted therapy, the named product matters more than a generic therapy label.
Domestic vs international route
Ask which department issues the quote and whether international-service charges are included.
Pathology, imaging and biomarkers
Repeat pathology, PET-CT, molecular tests and planning scans can materially change the bill.
ICU and toxicity policy
For intensive treatments, ask what happens financially if monitoring or hospital stay extends.
Bed days and extra-day rate
A package is incomplete if it gives no price for extra inpatient days or repeat visits.
Travel, hotel and companion
Independent studies show non-medical costs are real; foreign patients should calculate them separately from the hospital invoice.
What to Send Before Asking “How Much?”
Minimum clinical packet
- Pathology report and exact diagnosis
- Stage and recent CT / MRI / PET-CT as relevant
- Molecular / biomarker results when relevant
- Previous surgery, radiation and systemic treatment
- Current medicines and major comorbidities
Ask the hospital to itemize
- Exact treatment / protocol / product name
- Diagnostics and procedure charges
- Drugs and consumables included vs excluded
- Room, nursing, anesthesia and monitoring
- Extra-day, complication, deposit and refund rules
How a Case-Specific Estimate Is Prepared
Define the treatment basket
Start with pathology, stage, imaging and previous treatment rather than a target budget alone.
Separate benchmark from quote
Domestic cost research, list prices and historical fees stay separate from the hospital’s current offer.
Check the written estimate
Review inclusions, exclusions, extra-day rules, product identity, monitoring and major cost risks before travel.
Need a current hospital estimate for your case?
Send the medical file and any quote you already have. The request is for an itemized case-specific estimate. Sending records does not guarantee treatment, eligibility, acceptance, a price or a response time.
Cost drivers a quote still has to name
The eight cards above already separate diagnosis, method, product, hospital route, diagnostics, complications, stay, and non-medical costs. A written estimate should also name these lines when they apply. None of them has a universal price on this page, and this page does not publish a savings percentage.
- Cancer type, stage, and previous treatment
- Surgery, when surgery is part of the plan
- Hospital stay, including extra days
- Chemotherapy regimen and the number of cycles
- The targeted drug, if one is proposed
- Immunotherapy, kept separate from chemotherapy
- CAR-T or another cell therapy, only for a named product and indication
- Radiotherapy, kept separate from proton or heavy-ion therapy
- Proton or heavy-ion therapy, only if that modality is actually proposed
- Interventional or other local procedures
- Molecular testing
- PET/CT or other imaging, only when the plan uses it. Not every cancer file needs PET/CT.
- International-patient service fees, if the international route adds them
The oncology records list is on cancer treatment in China. Access compared with care at home, without a country ranking, is on cancer treatment in China vs the US.
Related China Cancer Guides
Frequently Asked Questions
Direct answers about China cancer costs, CAR-T, satri-cel, SPHIC and hospital quotes.
Is there one fixed price for cancer treatment in China?
No. The best independent Chinese studies show that cost changes by cancer type, treatment phase, stage, hospital type and region. International self-pay quotes also differ from domestic patient-cost studies and insurance-adjusted figures.
What do independent China-wide patient-cost studies show?
A 2024 multicentre cost-of-illness study of 13,745 patients across 84 hospitals in 17 provinces found median total costs of about USD 6,359–13,704 during initial treatment, USD 8,890–14,572 during relapse or metastasis, and USD 1,840–4,431 during follow-up. These are domestic patient-borne costs from 2021–2022, not international-patient package prices.
How much does surgery cost in China?
There is no national 2026 surgery tariff that applies across cancers and hospitals. FUDA published provider examples such as RMB 50,000–80,000 for early-stage laparoscopic surgery and RMB 80,000–120,000 for robotic-assisted surgery, but those examples are not independent national benchmarks and should not be used as a guaranteed quote.
How much does chemotherapy or immunotherapy cost in China?
There is no single national per-cycle price. The bill depends on the exact drugs, dose, cycle count, procurement route, insurance status, supportive medicines and hospital. Generic web ranges vary too widely to use as a reliable patient quote.
How much does proton or heavy-ion therapy cost at SPHIC?
An official Chinese government report from 2016 stated that a typical course at the Shanghai Proton and Heavy Ion Center cost nearly RMB 278,000. That is a historical official reference, not a current 2026 tariff. A current written SPHIC estimate should be requested for the individual case.
How much do approved CAR-T products cost in China?
A 2024 peer-reviewed paper reported list prices of RMB 999,000–1.29 million per infusion for five approved CAR-T products in China at that time. Those are product list prices, not complete treatment-episode costs; conditioning, procedures, hospitalization, monitoring and toxicity management can add further charges.
How much does satri-cel cost in China?
Shanghai's official information platform reported a price of RMB 990,000 for a course of satri-cel in August 2026. Satri-cel was approved in China in June 2026 for a specific CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal-junction cancer population after at least two prior lines. The product price is not automatically the complete hospital episode.
Does the 2024 Chinese cost study predict what an international patient will pay?
No. It is valuable evidence about the economic burden borne by patients in China, but it includes the Chinese care and insurance context. International patients need a case-specific self-pay estimate from the hospital or international department.
What should I send to get a meaningful estimate?
Send pathology, exact diagnosis and stage, recent imaging, molecular or biomarker results when relevant, prior treatments and responses, current medicines, major comorbidities and any quote you have already received.
What should a written hospital estimate include?
At minimum: the proposed treatment or product name, diagnostics, procedure or drug charges, planned hospitalization, anesthesia when relevant, imaging guidance, supportive medicines, monitoring, ICU or toxicity policy when relevant, extra-day rates, deposit and refund rules, and major exclusions.
How do I get a treatment estimate from a Chinese hospital?
Send the clinical file and ask the hospital or its international office for a written itemized estimate for a named treatment. The button on this page starts that request. The estimate is not a final bill, and it does not mean the hospital has accepted the case.
Sources and Evidence
- Independent multicentre cost-of-illness study (2024). 13,745 patients, 84 hospitals, 17 provinces; 2021–2022 data. PMC11429825.
- Systematic review (2023). 38 quantitative studies of cancer costs and financial burden in mainland China. PMID 37623036.
- Peer-reviewed CAR-T pricing paper (2024). Five approved China CAR-T products and published list prices. PMC11365067.
- Satri-cel approval (24 Jun 2026 government report). Indication and 22 June NMPA approval. Pudong Government.
- Satri-cel commercial price (20 Aug 2026). Shanghai official information platform reported RMB 990,000 per course. Shanghai Information Office.
- Satri-cel randomised phase 2 trial. Efficacy and safety context for CT041-ST-01. PMID 40460847.
- SPHIC historical official fee. National Health Commission report from 2016 stating nearly RMB 278,000 for a typical course at that time. China NHC.
- FUDA provider-published examples (20 Sep 2025). Used only as provider examples, not independent national benchmarks. FUDA official article.
Freshness note: current treatment prices, drug access, hospital packages, doctor schedules and international-patient billing can change. Verify the actual written proposal before travel or payment.
Medical note: this page explains cost evidence and quote structure. It does not diagnose cancer, recommend a treatment, guarantee eligibility or replace multidisciplinary oncology advice.
Get the Treatment Basket Right Before Comparing Prices
Send pathology, stage, imaging, previous treatment and any quote you already have. The request is for a current itemized estimate with inclusions, exclusions and major cost risks. A published figure is not that estimate, and an estimate is not the final bill.
✓ Independent evidence separated from provider claims
✓ Historical fees labelled historical
✓ Product price separated from hospital episode
✓ No universal package-price claim
Breast cancer has no single package price here. A figure needs the pathology report and the drug names. Breast cancer treatment in China says what a quote has to show.
Request an itemized cancer treatment estimate
There is no universal cancer-treatment price. Start with pathology, stage, current imaging and prior treatment. A useful estimate should separate diagnostics, procedure or drugs, hospital stay, repeat cycles and exclusions.